期刊
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
卷 18, 期 6, 页码 822-840出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2011.09.003
关键词
Mesenchymal stromal cells; MSC; Graft-versus-host disease; GVHD; Allogeneic hematopoietic cell transplantation
资金
- FNRS
- Belgian Foundation against Cancer (FBC)
- anticancer foundation from ULg
- CHU of Liege
- Terry Fox Foundation
- Belgian Government
- National Institutes of Health, Bethesda, MD [CA78902, HL36444]
Mesenchymal stromal cells (MSCs) represent a heterogeneous subset of multipotent cells that can be isolated from several tissues including bone marrow and fat. MSCs exhibit immunomodulatory and anti-inflammatory properties that prompted their clinical use as prevention and/or treatment for severe graft-versus-host disease (GVHD). Although a number of phase I-II studies have suggested that MSC infusion was safe and might be effective for preventing or treating acute GVHD, definitive proof of their efficacy remains lacking thus far. Multicenter randomized studies are ongoing to more precisely assess the impact of MSC infusion on GVHD prevention/treatment, whereas further research is performed in vitro and in animal models with the aims of determining the best way to expand MSCs ex vivo as well as the most efficient dose and schedule of MSCs 'administration. After introducing GVHD, MSC biology, and results of MSC infusion in animal models of allogeneic hematopoietic cell transplantation, this article reviews the results of the first clinical trials investigating the use of MSC infusion as prevention or treatment of GVHD. Biol Blood Marrow Transplant 18: 822-840 (2012) (C) 2012 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据